LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course
QR-110 was well-tolerated with no serious adverse events
… ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Top-line … that our daughter would one day be blind. Now, in early clinical testing we have seen the potential for sepofarsen to … and the therapeutic potential thereof, including timing of clinical trials and results from such clinical trials. …
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for … including commencement of the Sirius and Celeste trials, trial designs, site locations and timing of results from this …
This website contains forward-looking statements about potential therapeutic uses and effects of ProQR Therapeutics’ products, including but not limited to our technologies.